Company Profile

Cellular Dynamics International Inc (AKA:CDI)
Profile last edited on: 11/19/2015            CAGE: 474X4

Stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration
Year Founded
2004
1st Award Year
2007
Latest Award
2008
Program Status
Inactive (Acquired)
Popularity Index

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

525 Science Drive
Madison, WI 53711
   (608) 310-5100
   info@cellulardynamics.com
   www.cellulardynamics.com
Multiple Locations:   
Congressional District:   02
County:   Dane

Public Profile

In March 2015, Cellular Dynamcis was acquired by FujiFilm Holdings and in May ceased trading. Cellular Dynamics International, Inc. (CDI) is developing the next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. Cellular Dynamics International, Inc. (CDI) is developing stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual’s stem cell line created from a standard blood draw. CDI was founded by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : ICEL
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2008 2 NIH $499,796
Human Embryonic Stem Cell-Derived Cardiomyocytes for In Vitro Drug Screening

Key People / Management

  Robert J Palay -- CEO

  Timothy Daley -- Vice President And Interim Chief Financial Officer

  Jiaqiang He

  Emile Nuwaysir -- Vice President of Research and Development, Manufacturing Quality Systems, Chief

  Thomas M Palay -- President

  Chris Parker -- Vice President and Chief Commercial Officer

  Nicholas Seay -- Vice President and Chief Technology Officer

  David Snyder -- Vice President and Chief Financial Officer

  James A Thomson -- Chief Scientific Officer